Phospho-RPS6KA1 (S380) Antibody

What is RPS6KA1 and what signaling pathways involve this kinase?

RPS6KA1 (RSK1) belongs to the 90 kDa ribosomal S6 kinase family, functioning as a serine/threonine kinase primarily within the MAPK signaling cascade. It operates downstream of ERK1/2 signaling and plays crucial roles in cellular proliferation, survival, and differentiation. RPS6KA1 mediates mitogenic and stress-induced activation of several transcription factors including CREB1, ETV1/ER81, and NR4A1/NUR77. Additionally, it regulates translation through phosphorylation of substrates such as RPS6 and EIF4B, while also modulating mTOR signaling and repressing pro-apoptotic functions of proteins like BAD and DAPK1 .

The kinase is widely expressed and serves as an important effector in multiple receptor-mediated pathways. When activated, RPS6KA1 contributes to diverse cellular processes including gene expression, protein synthesis, cell cycle regulation, and cell survival mechanisms .

Why is phosphorylation at Serine 380 significant for RPS6KA1 function?

Phosphorylation at Serine 380 represents a critical regulatory event in RPS6KA1 activation and function. This site undergoes autophosphorylation as part of the activation process of RPS6KA1, creating a specific docking site for phosphoinositide-dependent kinase 1 (PDK1) . The creation of this docking site enables PDK1 to subsequently phosphorylate Serine 221 in the activation loop of the N-terminal kinase domain, further enhancing RPS6KA1 activity .

The S380 phosphorylation site is particularly significant because:

• It represents a key step in the sequential activation mechanism of RPS6KA1

• It creates a critical protein-protein interaction site for PDK1 binding

• It serves as an indicator of active RPS6KA1 in cellular contexts

• It functions as a regulatory node that can be modulated by upstream signals

The phosphorylation status at S380 therefore provides researchers with a valuable readout of RPS6KA1 activation in various experimental contexts and signaling environments .

How does the phosphorylation cascade leading to S380 phosphorylation work?

The phosphorylation of RPS6KA1 at S380 occurs through a sequential activation process that involves multiple phosphorylation events. The cascade begins with activation of the MAPK/ERK pathway, typically through receptor tyrosine kinase stimulation or other mitogenic signals .

The sequence of events includes:

• ERK1/2 activation through the RAF/MEK/ERK pathway

• ERK-mediated phosphorylation of RPS6KA1 at T573 (not always detected in experiments)

• This initial phosphorylation enables the autophosphorylation of RPS6KA1 at S380

• S380 phosphorylation provides a docking site for PDK1

• PDK1 then phosphorylates S221 in the activation loop of the N-terminal kinase domain

• ERK may also phosphorylate RPS6KA1 at T359 and S363 in the kinase linker region

While S221 is constitutively phosphorylated by PDK1 at the plasma membrane, full activation of RPS6KA1 requires phosphorylation at multiple sites, including S363 and S380 . Inhibition of upstream components, such as FGFR with SU5402, can suppress this phosphorylation cascade by inhibiting ERK activity, demonstrating the hierarchical nature of this signaling pathway .

What are the validated applications for Phospho-RPS6KA1 (S380) Antibody?

Phospho-RPS6KA1 (S380) antibodies have been validated for several research applications, with Western Blot (WB) and ELISA being the most thoroughly verified methods . The validation data for these applications demonstrates reliable and specific detection of the phosphorylated form of RPS6KA1 at Serine 380.

When designing experiments, researchers should prioritize applications with extensive validation data, particularly Western Blot, which has been demonstrated in multiple published studies . For applications with limited validation, additional optimization and controls may be required to ensure reliable results.

What are the recommended dilutions and detection parameters for Western Blot applications?

For optimal results in Western Blot applications, Phospho-RPS6KA1 (S380) antibodies should be used within specific dilution ranges established through validation experiments. These parameters ensure sufficient sensitivity while minimizing background signal.

It is highly recommended to titrate the antibody for each specific experimental system to achieve optimal results. The antibody concentration may need adjustment based on the expression level of the target protein, the detection method employed, and the specific cell type or tissue being examined .

What are the storage and handling recommendations for maintaining antibody activity?

Proper storage and handling of Phospho-RPS6KA1 (S380) antibody is essential for maintaining its specificity and sensitivity. The following guidelines should be followed to preserve antibody activity over time:

Following these recommendations will help ensure reliable experimental results and extend the useful life of the antibody. Always check the manufacturer's specific storage instructions, as formulations may vary slightly between suppliers .

How should experiments be designed to effectively study RPS6KA1 phosphorylation at S380?

Designing effective experiments to study RPS6KA1 phosphorylation at S380 requires careful consideration of controls, treatments, and biological context. A comprehensive experimental design should include:

Essential controls:

• Positive control: Calyculin A-treated HeLa cells consistently show phosphorylation at this site

• Negative control: Samples treated with phosphatase or specific inhibitors of upstream pathways

• Loading control: Total RPS6KA1 antibody on parallel blots or after stripping

• Specificity control: Competing phosphopeptide blocking

Treatment considerations:

• Time course experiments (5-60 minutes) to capture the dynamic nature of phosphorylation

• Dose-response studies with activators (growth factors) or inhibitors (MEK/ERK inhibitors)

• Include phosphatase inhibitors in all lysis buffers to preserve phosphorylation status

Cell system selection:

• Consider endogenous expression levels of RPS6KA1 in your model system

• FGFR2-dependent cell lines like SUM52 and MFM223 show differential phosphorylation patterns at S380

• IFNλ-sensitive cells can be used to study RPS6KA1 in the context of interferon signaling

A well-designed experiment should also consider the interrelationship between different phosphorylation sites (S221, S363, S380, T573) to fully understand the activation status of RPS6KA1 in the biological context being studied .

What sample preparation protocols optimize detection of phospho-RPS6KA1 (S380)?

Proper sample preparation is critical for reliable detection of phosphorylated RPS6KA1 at S380. The phosphorylation state can be easily lost during sample processing without appropriate precautions.

Recommended cell lysis protocol:

• Wash cells twice with ice-cold PBS

• Add lysis buffer containing:

  • 50 mM Tris-HCl (pH 7.5)

  • 150 mM NaCl

  • 1% NP-40 or Triton X-100

  • 5 mM EDTA

  • Critical phosphatase inhibitors: 10 mM sodium fluoride, 1 mM sodium orthovanadate, 10 mM β-glycerophosphate, 1 mM PMSF

  • Protease inhibitor cocktail

• Incubate on ice for 20 minutes with occasional vortexing

• Centrifuge at 14,000 × g for 15 minutes at 4°C

• Collect supernatant and determine protein concentration

• Add Laemmli buffer and heat at 95°C for 5 minutes

Important considerations:

• Process samples rapidly at 4°C to minimize dephosphorylation

• Avoid excessive freeze-thaw cycles of lysates

• For tissues, snap-freeze immediately after collection

• Consider using phospho-protein enrichment techniques for low abundance targets

• When loading SDS-PAGE gels, ensure equal protein loading (20-50 μg total protein)

Following these protocols will help preserve the phosphorylation status and improve detection sensitivity for phospho-RPS6KA1 (S380) in Western blot applications .

How can researchers induce or manipulate RPS6KA1 phosphorylation at S380 for experimental purposes?

Researchers can modulate RPS6KA1 phosphorylation at S380 through various experimental manipulations, which is useful for creating positive controls or studying pathway dynamics:

Methods to induce phosphorylation:

• Phosphatase inhibitors: Calyculin A treatment of HeLa cells has been validated as a positive control for S380 phosphorylation

• Growth factor stimulation: EGF, PMA, or insulin can activate the MAPK/ERK pathway leading to RPS6KA1 phosphorylation

• IFNλ treatment: In IFNλ-sensitive cells, treatment with type III interferon activates RSK1 and induces phosphorylation

Methods to inhibit phosphorylation:

• FGFR inhibitors: SU5402 inhibits FGFR kinase activity, suppressing ERK activation and subsequent RPS6KA1 phosphorylation in FGFR2-dependent cell lines

• MEK inhibitors: U0126 or PD98059 block ERK activation and downstream RSK1 phosphorylation

• ERK inhibitors: Direct inhibition of ERK1/2 prevents RPS6KA1 phosphorylation at multiple sites

Experimental design considerations:

• For induction, optimal treatment times typically range from 15-30 minutes for direct activators

• For inhibition studies, pre-treatment with inhibitors for 30-60 minutes before stimulation is recommended

• Concentration-dependent effects should be evaluated with dose-response experiments

These approaches provide researchers with tools to manipulate RPS6KA1 phosphorylation status in a controlled manner, facilitating studies on its role in various cellular processes and signaling pathways .

How does RPS6KA1 S380 phosphorylation contribute to translational regulation in IFNλ signaling?

The phosphorylation of RPS6KA1 at S380 plays a crucial role in mediating translational regulation in response to IFNλ stimulation. Research has revealed a sophisticated mechanism by which RPS6KA1 activation affects the translation initiation machinery.

In IFNλ-sensitive cells, non-activated RSK1 forms a complex with the translational repressor 4E-BP1. Upon IFNλ stimulation, RSK1 becomes phosphorylated at S380 and other sites, which triggers several critical events:

• The phosphorylated/activated RSK1 dissociates from the 4E-BP1 complex

• Simultaneously, 4E-BP1 dissociates from the translation initiation factor eIF4E

• This allows formation of the eIF4F complex, a critical step for cap-dependent translation

• Activated RSK1 also phosphorylates eIF4B, further enhancing translation initiation

This cascade of events leads to the upregulation of specific proteins, including p21(WAF1/CIP1), which contributes to the growth-inhibitory responses associated with IFNλ signaling .

The study of phospho-RPS6KA1 (S380) in this context has provided important insights into how type III interferons generate signals for mRNA translation of IFNλ-activated genes, complementing our understanding of transcriptional activation mechanisms in this pathway .

How do different phosphorylation sites on RPS6KA1 interact and influence each other?

RPS6KA1 activation involves a complex interplay between multiple phosphorylation sites that function in a coordinated and hierarchical manner. Understanding these relationships is critical for interpreting experiments involving phospho-specific antibodies.

The key phosphorylation sites and their relationships include:

• T573 phosphorylation (by ERK) is a prerequisite for S380 autophosphorylation, establishing a dependency relationship

• S380 autophosphorylation creates a docking site for PDK1, which then phosphorylates S221, demonstrating how one phosphorylation event enables another

• S221 phosphorylation (by PDK1) occurs in the activation loop of the N-terminal kinase domain and can be constitutively phosphorylated at the plasma membrane but also depends on S380 phosphorylation for full activation

• S363 phosphorylation (by ERK) in the N-terminal kinase linker region contributes to increased activity that also depends on S221 and S380 phosphorylation

Differential phosphorylation patterns can be observed in response to inhibitors. For example, in FGFR2-dependent breast cancer cell lines (SUM52 and MFM223), treatment with the FGFR inhibitor SU5402 produced distinct effects:

• S221 remained constitutively phosphorylated in both cell lines

• S363 phosphorylation was significantly reduced in SUM52 but not MFM223

• S380 phosphorylation was inhibited in MFM223 but not detected in SUM52

These observations highlight the complex dynamics and cell-type specific regulation of RPS6KA1 phosphorylation, requiring researchers to carefully consider which phosphorylation sites to monitor when studying RSK1 activation .

What are the methodological approaches for studying RPS6KA1 crosstalk with other signaling pathways?

Investigating the crosstalk between RPS6KA1 and other signaling pathways requires sophisticated experimental approaches that can capture the dynamic interplay between multiple cellular processes. Several methodological strategies are particularly effective:

1. Phosphoproteomic Analysis:

• Differential phosphoproteomics can reveal how inhibition of one pathway (e.g., FGFR signaling) affects phosphorylation events across multiple pathways, including RPS6KA1 and its targets

• SILAC or TMT labeling combined with phosphopeptide enrichment and mass spectrometry provides quantitative insights into phosphorylation dynamics

• Bioinformatic analysis of phosphoproteomic data can identify signaling nodes and pathway interactions

2. Sequential Inhibitor/Activator Studies:

• Pretreatment with pathway-specific inhibitors followed by stimulation helps dissect hierarchical relationships

• Example approach:

  • Pretreat cells with MEK inhibitor (U0126)

  • Stimulate with IFNλ

  • Assess phospho-S380 RPS6KA1 levels

  • This reveals whether IFNλ-induced RPS6KA1 activation requires MEK/ERK signaling

3. Protein-Protein Interaction Studies:

• Co-immunoprecipitation using phospho-S380 RPS6KA1 antibody can identify interaction partners specific to the activated form

• Proximity ligation assays can visualize in situ interactions between phosphorylated RPS6KA1 and pathway components

• Analysis of RSK1 complexes with 4E-BP1 before and after stimulation reveals mechanistic insights into translational regulation

4. Genetic Manipulation Combined with Phosphorylation Analysis:

• Site-directed mutagenesis of key phosphorylation sites (S221, S363, S380, T573) followed by functional assays

• CRISPR-Cas9 editing of pathway components with subsequent analysis of phospho-RPS6KA1 status

• Expression of phosphomimetic or phosphodeficient RPS6KA1 mutants to study downstream effects

These approaches, individually or in combination, provide powerful tools for understanding how RPS6KA1 signaling integrates with other pathways, particularly in contexts like cancer where multiple signaling networks operate simultaneously .

How should researchers interpret changes in phospho-RPS6KA1 (S380) levels in different experimental contexts?

Interpreting changes in phospho-RPS6KA1 (S380) levels requires careful consideration of experimental context, biological system, and the relationship to other signaling events. Here are key principles for rigorous interpretation:

Quantitative Assessment:

• Always normalize phospho-RPS6KA1 (S380) signal to total RPS6KA1 to account for expression level differences

• Consider the fold change relative to basal state rather than absolute signal intensity

• Use appropriate statistical analysis to determine significance of observed changes

Contextual Interpretation:

• In growth factor stimulation: Rapid increases in phospho-S380 (within 5-30 minutes) typically indicate normal MAPK pathway activation

• In FGFR-dependent cancer cells: Constitutive phosphorylation may indicate oncogenic dependency, while inhibitor-induced reduction suggests pathway addiction

• In IFNλ signaling: Increased phosphorylation correlates with translational activation and specific gene expression patterns

• In drug response studies: Differential sensitivity of S380 phosphorylation compared to other sites may indicate pathway-specific effects

Interpretation Pitfalls to Avoid:

• Don't interpret changes in isolation; always consider other phosphorylation sites (S221, S363, T573)

• Be cautious about inferring full RSK1 activation from S380 phosphorylation alone

• Consider cell-type specificity; the same stimulus may produce different phosphorylation patterns in different cell types

• Account for timing; transient vs. sustained phosphorylation may have different biological meanings

Biological Significance Framework:

• Correlate phosphorylation changes with downstream functional outcomes (proliferation, survival, translation)

• Consider phosphorylation in the context of pathway networks rather than linear cascades

• Remember that S380 serves as both an indicator of activation and a regulatory mechanism for further activation via PDK1 recruitment

By following these interpretative guidelines, researchers can extract meaningful biological insights from phospho-RPS6KA1 (S380) data across diverse experimental settings .

What is the significance of RPS6KA1 S380 phosphorylation in disease contexts and therapeutic targeting?

The phosphorylation status of RPS6KA1 at S380 has emerging importance in disease pathophysiology and as a potential biomarker for therapeutic response, particularly in cancer and inflammatory conditions.

Cancer Relevance:

• In FGFR2-addicted triple-negative breast cancer cell lines, differential patterns of RPS6KA1 phosphorylation at S380 correlate with sensitivity to FGFR inhibitors

• SU5402 (an FGFR inhibitor) suppresses Rsk1 activity via inhibition of ERK activity in these cell lines, suggesting phospho-RPS6KA1 (S380) could serve as a pharmacodynamic biomarker for FGFR-targeted therapies

• The integration of RPS6KA1 with translational machinery suggests it may contribute to dysregulated protein synthesis in malignant cells

Therapeutic Implications:

• As a downstream biomarker: Monitoring phospho-RPS6KA1 (S380) levels can provide insights into the efficacy of upstream kinase inhibitors (RAF, MEK, ERK, FGFR)

• As a therapeutic target: Direct inhibition of RSK1 could potentially overcome resistance to upstream inhibitors

• In combination strategies: Understanding the phosphorylation dynamics can inform rational drug combinations that target multiple nodes in the signaling network

In Inflammatory Conditions:

• The role of RPS6KA1 in IFNλ signaling suggests its phosphorylation status may be relevant in viral infections and inflammatory diseases where interferons play critical roles

• Phosphorylated RPS6KA1 mediates translational control of specific genes involved in growth inhibition (p21WAF1/CIP1), potentially linking it to cell cycle arrest in inflammatory responses

Methodological Considerations for Disease Research:

• Patient-derived samples require special attention to preserve phosphorylation status during collection and processing

• Immunohistochemistry protocols for tissue samples need validation specifically for phospho-epitopes

• Multi-parametric analysis combining phospho-RPS6KA1 (S380) with other pathway markers provides more comprehensive insights

These findings collectively highlight the potential of phospho-RPS6KA1 (S380) as both a mechanistic research tool and a clinically relevant biomarker in pathological contexts involving MAPK pathway dysregulation .

What emerging technologies might enhance the study of RPS6KA1 phosphorylation dynamics?

Several cutting-edge technologies are poised to revolutionize our understanding of RPS6KA1 phosphorylation dynamics, offering greater temporal and spatial resolution than traditional methods:

• Single-cell phosphoproteomics: This emerging technology allows measurement of phosphorylation states at the individual cell level, revealing heterogeneity in RPS6KA1 activation that may be masked in bulk cell analysis

• Phospho-specific intrabodies and biosensors: Development of phospho-S380-specific intracellular antibodies or FRET-based biosensors would enable real-time visualization of RPS6KA1 activation in living cells

• Mass cytometry (CyTOF): Incorporating phospho-RPS6KA1 (S380) antibodies into CyTOF panels enables multi-parametric analysis of signaling networks at single-cell resolution across diverse cell populations

• Spatial proteomics techniques: Methods like imaging mass cytometry or multiplexed ion beam imaging can map the subcellular localization of phosphorylated RPS6KA1 in relation to other signaling components

• Proximity-dependent labeling approaches: BioID or APEX2 fusions with RPS6KA1 can identify proximity interactions that change upon S380 phosphorylation, revealing dynamic signaling complexes

• Cryo-electron microscopy: Structural studies of RPS6KA1 in different phosphorylation states could provide mechanistic insights into how S380 phosphorylation alters protein conformation and activity

These technological advances, when applied to the study of RPS6KA1 phosphorylation, promise to reveal new insights into the spatiotemporal regulation of this important signaling node and its role in diverse cellular processes .

What are the key unresolved questions regarding RPS6KA1 S380 phosphorylation for future research?

Despite significant advances in understanding the role of S380 phosphorylation in RPS6KA1 function, several critical questions remain unanswered, presenting opportunities for future research:

• Temporal dynamics and thresholds: What are the precise kinetics of S380 phosphorylation relative to other sites, and is there a threshold level required for biological effects?

• Subcellular localization effects: How does S380 phosphorylation influence the subcellular distribution of RPS6KA1, and does this contribute to substrate specificity?

• Pathway specificity: Are there stimulus-specific patterns of RPS6KA1 phosphorylation that encode different downstream responses?

• Regulatory mechanisms: What phosphatases target S380 specifically, and how is their activity regulated in different cellular contexts?

• Translational integration: Beyond the established role in IFNλ signaling, how does phospho-RPS6KA1 (S380) selectively influence the translation of specific mRNAs?

• Crosstalk with other modifications: How do other post-translational modifications (methylation, ubiquitination, acetylation) interact with S380 phosphorylation to regulate RPS6KA1?

• Therapeutic resistance mechanisms: How do alterations in RPS6KA1 phosphorylation contribute to resistance against targeted therapies in cancer?

• Isoform-specific functions: How does S380 phosphorylation differentially affect the function of RSK family members (RSK1-4) in various tissues?